Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/4051
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTashmatova Gulnoza Aloyevna-
dc.date.accessioned2022-10-13T11:55:29Z-
dc.date.available2022-10-13T11:55:29Z-
dc.date.issued2022-
dc.identifier.urihttp://repository.tma.uz/xmlui/handle/1/4051-
dc.description.abstractWith the emergence of a new disease COVID-19 (CoronaVIrus Disease-2019), caused by the coronavirus SARS-CoV-2, the usual pattern of interaction between a doctor and a patient has changed significantly. During the COVID-19 pandemic, it was assumed that patients with allergies and asthma would be at higher risk of developing severe illness, but after analyzing statistics from different countries, it was concluded that asthma and allergies are not common comorbidities during the COVID-19 pandemic and According to the results of recently published studies, it has not been proven that allergies and allergic asthma are risk factors for exacerbations of asthma caused by the COVID-19 virus, as well as factors for the development of severe COVID-19, and are not factors that increase the risk of death from COVID-19.en_US
dc.language.isoenen_US
dc.publisherПавлодар, Казахстанen_US
dc.subjectChildren; bronchial asthma; new coronavirus infection; COVID- 19; clinic.en_US
dc.titleFeatures of the management of bronchial asthma during the COVID-19 pandemicen_US
dc.typeArticleen_US
Appears in Collections:Thesis, Articles

Files in This Item:
File Description SizeFormat 
17.. Казакстан 17.05.2022 Ташматова Г.А..pdfFeatures of the management of bronchial asthma during the COVID-19 pandemic3.87 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.